Vendor Intelligence Report: Amino Asylum

Executive summary

Amino Asylum is no longer a simple vendor-score case. Across 15 Finnrick lab tests, the vendor passed 7 and failed 8, for a 47% overall pass rate. The catalog is uneven: Semaglutide and Melanotan II are the comparatively stronger side of the legacy sample set, while BPC-157 and CJC-1295 failed both tested samples. Ratings also compress under stricter grading, so the headline is product-specific legacy signal, not proof of Soma Chems batches.

The investigation follows what happened after Amino Asylum rather than treating the old storefront as dead. The aminoasylum.shop domain routed to a coupon landing page promoting Soma Chems; GymNTonic publicly labeled a SomaChems product as formerly Amino Asylum; and the same Delaware address appears across successor materials. That is strong market-facing continuity, but not a clean corporate ownership trail.

The recourse picture is thin. The original Kentucky LLC is documented as administratively dissolved, and a Delaware search found no Soma Chems entity under the searched names despite use of a Delaware address. The report also separates secondary reporting of the June 2025 FDA raid from the absence of a public related indictment, and flags why prescription-medication catalog overlap and affiliate codes matter to buyers trying to authenticate a vial.

Inside the full report:

• Appendix A laboratory table with per-product pass/fail rates, rating trajectories, and methodology-divergence charts for all 8 tested products
• Dated successor-route timeline from Amino Asylum to Soma Chems and GymNTonic
• Kentucky and Delaware corporate-record review, including dissolved-entity and no-record search exhibits
• Domain and channel authentication map covering redirects, coupon pages, Soma Chems, GymNTonic, and clone-risk signals
• Affiliate-promotion scan of X, Reddit, blogs, and coupon aggregators with disclosure classifications
• Risk matrix tying lab failures, batch-ID gaps, regulatory exposure, and buyer recourse into product-specific guidance

Risk assessment

• Product-specific quality-control risk — high: BPC-157 45.16% with 0/2 pass, CJC-1295 24.11% with 0/2 pass, and PT-141 failing its only test are weak historical Amino Asylum choices; Semaglutide and Melanotan II performed better and are not the concern.
• Unverifiable COA and batch-traceability risk — high: Finnrick-tested Amino Asylum samples lacked batch IDs, and Soma Chems’ 99% purity claims were not shown with consistently verifiable batch-specific third-party COAs in the supplied materials.
• Federal enforcement and successor-continuity risk — high: Amino Asylum reportedly ceased orders after a June 2025 FDA raid; aminoasylum.shop now routes traffic toward Soma Chems, creating shutdown, refund, service, and successor-authentication risk.
• Corporate registration and buyer-recourse opacity — high: Amino Asylum LLC was administratively dissolved in Kentucky in 2021, and no Delaware registration for Soma Chems was found under the searched names despite use of a Delaware address.
• Prescription-drug catalog regulatory risk — high: Amino Asylum’s archived catalog and the current GymNTonic channel place peptides next to prescription or regulated drug names, increasing enforcement and continuity risk for buyers.
• Copycat and brand-confusion risk — high: Post-shutdown lookalike risk, legacy redirects, coupon pages, and the absence of a clear official-channel or anti-counterfeit system make it difficult to verify genuine Amino Asylum / Soma Chems sourcing.
• Undisclosed affiliate-promotion risk — medium: The affiliate scan found 14 promoter records; 13 carried a referral code or link, with 0 clear disclosures among referral-carrying promoters.